Tesamorelin
Approved medicineThe FDA has approved a version of this as a medicine, so it has been through large studies in people.
Also called Egrifta / TH9507 / GRF 1-44 analogue
A copy of the natural growth hormone signal, approved to reduce deep belly fat in people living with HIV.
The basics
- What is it?
- An approved medicine that copies the natural brain signal for releasing growth hormone.
- What do we know?
- In people living with HIV who carry extra deep belly fat, it reduces that fat. That is what it is approved for.
- What do we still not know?
- Whether it helps anyone outside that specific group.
Can a doctor prescribe this?
Yes. Pharmacies are allowed to make it, so a doctor can write a prescription for it.
The FDA has approved a version of this as a medicine.
FDA approved for HIV-associated lipodystrophy and legally available by prescription.
Official status: On the 503A bulks list. Checked 2026-06-05.
Lab suppliers we list: 15
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
In human trials
2 mg
under the skin · daily
Body Composition and Adipose Tissue in HIVPHASE4 · NCT03226821
“Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily.”
1.4 mg
once a day · for 6 months
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected PersonsPHASE2 · NCT02572323
“1.4mg of tesamorelin is injected once a day for 6 months, then no treatment is given for 6 months.”
2 mg
under the skin · daily · for 6 months
Tesamorelin Effects on Liver Fat and Histology in HIVNA · NCT02196831
“tesamorelin 2mg subcutaneously daily x 12 months double-blind phase.”
See source wording
under the skin · once daily
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)PHASE2 · NCT07481734
“for injection, 2 mg SC once daily; participant self-administration after training.”
See source wording
under the skin · daily
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskPHASE2 · NCT03375788
“Tesamorelin F4 formulation 1.4mg daily.”
2 mg
under the skin · daily
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®PHASE4 · NCT01591902
“Daily 2 mg subcutaneous injections of tesamorelin.”
2 mg
under the skin · daily
Effect of Short Term Growth Hormone Releasing Hormone in Healthy MenNA · NCT00850564
“Tesamorelin 2mg subcutaneous daily x 2 weeks.”
2 mg
under the skin · daily
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®Not stated · NCT01579695
“Daily 2 mg subcutaneous injections of Tesamorelin.”
2 mg
under the skin · daily
Effects of Growth Hormone Releasing Hormone in HIVNA · NCT01263717
“Tesamorelin (growth hormone releasing hormone) 2mg daily given by subcutaneous injection x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose.”
1.28 mg
under the skin · daily
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVPHASE2 · NCT06554717
“Tesamorelin WR 1.28 mg given subcutaneously daily.”
See source wording
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle WastingPHASE2 · NCT01388920
“Tesamorelin 2 mg.”
- The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.
Study in people
eNeurologicalSci · 2026
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
Study in people
BMJ open · 2026
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
Study in people
The Journal of infectious diseases · 2025
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
Study in people
AIDS (London, England) · 2024
- Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.
Study in people
Journal of clinical and translational science · 2023
- Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.
Animal study, rats or mice
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026
- Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
- Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
Journal not recorded · 2026
- Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Journal of pharmaceutical and biomedical analysis · 2026
- Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.
Cureus · 2025
- Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
Journal of mass spectrometry : JMS · 2024
- Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.
Analytical biochemistry · 2023
- Pharmacoeconomic Review Report: Tesamorelin (Egrifta)
Journal not recorded · 2016
- CADTH Canadian Drug Expert Committee Final Recommendation: Tesamorelin: (Egrifta — Theratechnologies Inc.): Indication: HIV-associated lipohypertrophy
Journal not recorded · 2016
- Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.
Review of earlier work
Journal of the International Association of Providers of AIDS Care · 2026
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Review of earlier work
The American journal of sports medicine · 2026
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Review of earlier work
Frontiers in endocrinology · 2026
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Review of earlier work
Journal not recorded · 2026
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
Review of earlier work
Obesity research & clinical practice · 2026
- Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss.
Review of earlier work
Journal of clinical medicine · 2026
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Review of earlier work
Sports medicine (Auckland, N.Z.) · 2026
- Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
Review of earlier work
JBJS reviews · 2026
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Review of earlier work
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Review of earlier work
Journal not recorded · 2025
- Metabolic dysfunction-associated steatotic liver disease in people with HIV.
Review of earlier work
Current opinion in HIV and AIDS · 2025
- CROI 2024: Neuropsychiatric Complications in People With HIV.
Review of earlier work
Topics in antiviral medicine · 2024
- Causes and outcomes of hepatic fibrosis in persons living with HIV.
Review of earlier work
Current opinion in HIV and AIDS · 2022
- Clinical Review Report: Tesamorelin (Egrifta)
Review of earlier work
Journal not recorded · 2016